In the Margins
Valeant Pharmaceuticals has named Mason Morfit, a partner at activist hedge fund ValueAct Capital, to its board of directors. Morfit previously served on the embattled specialty drugmaker's board from 2007 to 2014; ValueAct is one of Valeant's largest shareholders. Read the original story from Forbes.
Most Read
Average compensation among mutual fund independent directors was higher in 2024, when compared to the year prior, an increase that was more than double what their ...
Comprehensive guidance on the oversight of sub-advisers that exists in the market has served mutual fund boards well for over 15 years. These frameworks remain foundational, ...
Independent directors who anticipate overseeing exchange-traded fund share classes are contemplating myriad issues related to what many industry participants believe will be a seismic shift in ...
Over the past several weeks, I have written articles exploring conflicts of interest that could challenge a variety of financial industry participants. Those articles explored potential ...